Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries, CA Cancer J Clin, vol.68, issue.6, pp.394-424, 2018. ,
Hepatocellular carcinoma in cirrhosis: incidence and risk factors, Gastroenterology, vol.127, issue.5, pp.35-50, 2004. ,
Global trends and predictions in hepatocellular carcinoma mortality, J Hepatol, vol.67, issue.2, pp.302-311, 2017. ,
Hepatocellular carcinoma: role of hepatitis B and hepatitis C viruses proteins in hepatocarcinogenesis, J Viral Hepat. sept, vol.11, issue.5, pp.383-93, 2004. ,
Molecular pathogenesis of human hepatocellular carcinoma, Nat Genet. août, vol.31, issue.4, pp.339-385, 2002. ,
, The Burden of Primary Liver Cancer and Underlying Etiologies From 1990 to 2015 at the Global, Regional, and National Level: Results From the Global
Risk prediction of hepatocellular carcinoma in patients with cirrhosis: The ADRESS-HCC risk model: The ADRESS-HCC Risk Model, Cancer, vol.120, issue.22, pp.3485-93, 2014. ,
Carcinogenèse hépatique et virus de l'hépatite C. médecine/sciences. mars, vol.18, pp.335-377, 2002. ,
How the risk of liver cancer changes after alcohol cessation: a review and meta-analysis of the current literature, BMC Cancer, vol.11, p.446, 2011. ,
De la stéatohépatite non alcoolique au carcinome hépatocellulaire : mécanismes physiopathologiques, Médecine Mal Métaboliques. févr, vol.5, issue.1, pp.38-44, 2011. ,
Randomized controlled trial of screening for hepatocellular carcinoma, J Cancer Res Clin Oncol. juill, vol.130, issue.7, pp.417-439, 2004. ,
Screening for hepatocellular carcinoma in cirrhosis, J Hepatol. 1 déc, vol.39, issue.6, pp.1076-84, 2003. ,
Meta-analysis: surveillance with ultrasound for early-stage hepatocellular carcinoma in patients with cirrhosis, Aliment Pharmacol Ther. juill, vol.30, issue.1, pp.37-47, 2009. ,
, Des-? Carboxyprothrombin, and Lectin-Bound ?-Fetoprotein in Early Hepatocellular Carcinoma, vol.137, pp.110-118, 2009.
Cost Effectiveness of Alternative Surveillance Strategies for Hepatocellular Carcinoma in Patients With Cirrhosis, Clin Gastroenterol Hepatol. déc, vol.6, issue.12, pp.1418-1442, 2008. ,
The Burden of Primary Liver Cancer and Underlying Etiologies From 1990 to 2015 at the Global, Regional, and National Level: Results From the Global Burden of Disease Study, JAMA Oncol. 1 déc, vol.3, issue.12, p.1683, 2015. ,
, Novel advancements in the management of hepatocellular carcinoma in 2008
,
Accuracy of Ultrasonography, Spiral CT, Magnetic Resonance, and Alpha-Fetoprotein in Diagnosing Hepatocellular Carcinoma: A Systematic Review. CME, Am J Gastroenterol. mars, vol.101, issue.3, pp.513-536, 2006. ,
, Place de la radiofréquence dans la destruction des tumeurs du foie
Liver Transplantation for Hepatocellular Carcinoma Without Preoperative Tumor Biopsy: Transplantation, vol.86, pp.1068-76, 2008. ,
Natural history and prognostic indicators of survival in cirrhosis: A systematic review of 118 studies, J Hepatol. janv, vol.44, issue.1, pp.217-248, 2006. ,
Liver transplantation for hepatocellular carcinoma: a model including ?-fetoprotein improves the performance of Milan criteria, Gastroenterology, vol.143, issue.4, pp.986-994, 2012. ,
URL : https://hal.archives-ouvertes.fr/inserm-00865368
Management of hepatocellular carcinoma: An update, Hepatology. mars, vol.53, issue.3, pp.1020-1022, 2011. ,
Sorafenib therapy in advanced hepatocellular carcinoma: the SHARP trial, Expert Rev Anticancer Ther. juin, vol.9, issue.6, pp.739-784, 2009. ,
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial, Lancet Oncol. janv, vol.10, issue.1, pp.25-34, 2009. ,
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial, The Lancet. mars, vol.391, pp.1163-73, 2018. ,
Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial, Lancet Lond Engl, vol.07, pp.56-66, 2017. ,
Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma, N Engl J Med. 5 juill, vol.379, issue.1, pp.54-63, 2018. ,
, CHC)
, Anatomie du foie -Cancer du foie
Foie et anomalies de perfusion en imagerie, vol.12, 2020. ,
Hepatocellular carcinoma vascularization: From the most common to the lesser known arteries, Diagn Interv Imaging. janv, vol.95, issue.1, pp.27-36, 2014. ,
HCC and angiogenesis: possible targets and future directions, Nat Rev Clin Oncol. mai, vol.8, issue.5, pp.292-301, 2011. ,
,
Patient Selection for Transarterial Chemoembolization in Hepatocellular Carcinoma: Importance of Benefit/Risk Assessment, Liver Cancer, vol.7, issue.1, pp.104-123, 2018. ,
, Traitement des tumeurs malignes du foie par radiologie interventionnelle : techniques intra-artérielles -Revue Médicale Suisse
,
Physiology and pharmacology of iodized oil in goiter prophylaxis, Medicine (Baltimore). janv, vol.80, issue.1, pp.20-36, 2001. ,
Hepatic artery injection of I-131-labeled lipiodol. Part I. Biodistribution study results in patients with hepatocellular carcinoma and liver metastases, Radiology. août, vol.168, issue.2, pp.541-546, 1988. ,
, Résumé des caractéristiques du produit -LIPIODOL ULTRA-FLUIDE 480 mg/ml, solution injectable -Base de données publique des médicaments
Mechanism of Action, Pharmacokinetics, Efficacy, and Safety of Transarterial Therapies Using Ethiodized Oil: Preclinical Review in Liver Cancer Models, J Vasc Interv Radiol JVIR, vol.29, issue.3, pp.413-437, 2018. ,
Role of Kupffer cells in iodized oil embolization. Invest Radiol, vol.29, pp.990-993, 1994. ,
Treatment of Liver Tumors with Lipiodol TACE: Technical Recommendations from Experts Opinion, Cardiovasc Intervent Radiol. mars, vol.39, issue.3, pp.334-377, 2016. ,
Endovascular Embolization by Transcatheter Delivery of Particles: Past, Present, and Future, J Funct Biomater. 3 avr, vol.8, issue.2, p.12, 2017. ,
Chimioembolisation des carcinomes hépatocellulaires : une vieille méthode au goût du jour, J Radiol Diagn Interv. juin, vol.96, issue.2, pp.162-71, 2015. ,
Chimioembolisation des carcinomes hépatocellulaires : une vieille méthode au goût du jour, 2015. ,
,
Quantification of tumor uptake of iodized oils and emulsions of iodized oils: experimental study, Radiology. déc, vol.201, issue.3, pp.731-736, 1996. ,
Transcatheter oily chemoembolization of hepatocellular carcinoma, Radiology. mars, vol.170, issue.3, pp.783-789, 1989. ,
Circulatory alterations induced by intra-arterial injection of iodized oil and emulsions of iodized oil and doxorubicin: experimental study, Radiology. janv, vol.194, issue.1, pp.165-70, 1995. ,
Overall survival after transarterial lipiodol infusion chemotherapy with or without embolization for unresectable hepatocellular carcinoma: propensity score analysis, AJR Am J Roentgenol. mars, vol.194, issue.3, pp.830-837, 2010. ,
Hepatocellular carcinoma: treatment with intraarterial iodized oil with and without chemotherapeutic agents, Radiology. mai, vol.163, issue.2, pp.345-51, 1987. ,
Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma, Hepatology. mai, vol.35, issue.5, pp.1164-71, 2002. ,
, A Comparison of Lipiodol Chemoembolization and Conservative Treatment for Unresectable Hepatocellular Carcinoma, N Engl J Med. 11 mai, vol.332, pp.1256-61, 1995.
Evolving strategies for the management of intermediate-stage hepatocellular carcinoma: available evidence and expert opinion on the use of transarterial chemoembolization, Cancer Treat Rev. mai, vol.37, issue.3, pp.212-232, 2011. ,
URL : https://hal.archives-ouvertes.fr/hal-01134844
Use of Lipiodol as a drug-delivery system for transcatheter arterial chemoembolization of hepatocellular carcinoma: A review, Crit Rev Oncol Hematol. déc, vol.88, issue.3, pp.530-579, 2013. ,
Use of Ethanol in the Trans-Arterial Lipiodol Embolization (TAELE) of Intermediated-Stage HCC: Is This Safer than Conventional Trans-Arterial Chemo-Embolization (c-TACE)?, PloS One, vol.10, issue.6, p.129573, 2015. ,
Transarterial Alcohol-Lipiodol Therapy in Patients with Hepatocellular Carcinoma Using Low Alcohol Concentrations, ROFO Fortschr Geb Rontgenstr Nuklearmed. juill, vol.188, issue.7, pp.676-83, 2016. ,
Embolization efficacy and treatment effectiveness of transarterial therapy for unresectable hepatocellular carcinoma: a case-controlled comparison of transarterial ethanol ablation with lipiodolethanol mixture versus transcatheter arterial chemoembolization, J Vasc Interv Radiol JVIR. mars, vol.20, issue.3, pp.352-361, 2009. ,